Seattle, WA -- (SBWIRE) -- 10/02/2019 -- Blepharitis is a chronic disorder that leads to inflammation of the eyelids. The disorder impacts the part of eyelid where eyelashes grow. The disease progresses when tiny oil glands near this area are clogged as the clogging leads to irritation and redness of the eyes. Blepharitis is evident with following symptoms: high sensitivity to light, loss of eyelashes, watery eyes, burning sensation in the eyes, greasy eyelids, itchy eyes, red and swollen eyes, flaking of skin around the eyes, crusted eyelashes after waking up, more frequent blinking, abnormal growth of eyelashes, and stinging sensation in the eyes. Blepharitis is also a cause of seborrheic dermatitis, a dandruff of the eyebrows and scalp. The condition can also lead to bacterial infection, clogged oil glands, malfunctioning of oil glands, and rosacea. Other effects include allergic reactions to eye medications, contact lens solutions or eye make-up and eyelash lice or mites.
Increasing prevalence of ophthalmic disorders among the geriatric population is expected to boost growth of the blepharitis treatment market. For instance, according to a survey conducted by American Academy of Ophthalmology in 2014, blepharitis usually affects people above the age of 50 years. According to the same source, blepharitis is observed in 37% male ophthalmic patients and 47% in female ophthalmic patients.
Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1761
Moreover, increasing number of drugs in the pipeline is also expected to contribute to the market growth. For instance, ISV-305 sponsored by InSite Vision is in phase 3 clinical trials, ISV-305 treats patients with early symptoms of blepharitis. Key players in the market are focused on product development and launch in order to expand their product portfolio, thereby propelling the market growth. For instance, in 2015, BlephEx, a Franklin-based company launched Rysurg. It is used to clean eyelids and also maintains hygiene. According to a study conducted by American Academy of Ophthalmology in 2015, around 50% of ophthalmic patients suffer from symptoms of blepharitis and dry eyes. Constant use of this device helps prevent recurrence of blephairis and the treatment is pain-free. Key players in the market are also focused on adopting merger and acquisition strategies. For instance, in 2013, Shire Plc. acquired California-based ophthalmic company, SARcode Bioscience. The acquisition helped Shire Plc. to add new drug – Lifitegrast— to its specialist drug portfolio. In 2016, the U.S. Food and Drug Administration (FDA) approved Lifitegrast for the treatment of signs and symptoms of dry eye and blepharitis.
However, lack of awareness regarding the treatment of blepharitis and high cost of therapies used in the treatment of the condition is expected to hinder the market growth.
For instance, in 2017, Scope Ophthalmic launched Moist Heat Mask, a device that helps in the treatment of blepharitis by loosening the oil present in Meibomian glands and allowing it to flow more freely. It helps to soften eye lash debris, prevent the evaporation of natural tear film, restores moisture to the eye and also the surrounding area, as well as improves tear film lipid quality. In 2015, MiBo Medical Group, a U.S.-based company, launched MibO Thermoflo. This device helps in the treatment of blepharitis and dry eyes and is required to be gently massaged on the margins of the eyelids for a minimum of 12 minutes. In 2015, MiBo Medical Group launched Lid Pro, a device that is used to treat anterior Blepharitis. The region of Asia Pacific is expected to witness significant growth due to increasing prevalence of blepharitis. According to a study conducted by Journal of Clinical and Experimental Ophthalmology in 2016, signs and symptoms of blepharitis increased by 32% among the geriatric population as compared to 2014.
Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1761
Blepharitis Treatment Market Taxonomy:-
The global Blepharitis treatment market is segmented based on disease type, treatment type, distribution channel, and region.
By Disease Type:-
Posterior Blepharitis
Anterior Blepharitis
Mixed Blepharitis
By Treatment Type:-
Antibiotic Therapy
Topical Corticosteroids
Topical Antibodies
Oral Antibodies
Ointments
Eye Cleansers
Others
By Distribution Channel:-
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:-
North America
Europe
Latin America
Asia-Pacific
Middle East
Africa
Blepharitis Treatment Market Key Players:-
Key players operating in the Blepharitis treatment market include Scope Ophthalmic Ltd, NovaBay Pharmaceuticals Inc, Thea Pharmaceuticals Ltd, Perrigo Laboratories, InSite Vision Incorporated, Merck & Co, and Novartis AG
To view the original version on The Express Wire visit https://www.coherentmarketinsights.com/ongoing-insight/blepharitis-treatment-market-1761
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.